Tander Burak, Rizalar Riza, Cihan Ahmet O, Ayyildiz Suat H, Ariturk Ender, Bernay Ferit
Department of Pediatric Surgery, Ondokuz Mayis University, Samsun 55139, Turkey.
Pediatr Surg Int. 2007 Jan;23(1):81-6. doi: 10.1007/s00383-006-1816-3. Epub 2006 Oct 17.
One-stage transanal pull-through (TAP) has become a standard definitive procedure for the treatment of Hirschsprung's disease (HD). Short-term results of this operation seem to be excellent, but long-term outcome is still obscure. We evaluated the morbidity and mortality of our patients with one-stage TAP, and we reviewed the literature. We performed a TAP without a colostomy in 21 patients with HD. The primary outcome measures are age, sex, complications during surgery, enterocolitis (EC) attacks after surgery, postoperative stooling problems and mortality. All patients were called over telephone, and their clinical and functional outcomes were obtained. Case series of TAP in the literature were also reviewed in terms of postoperative problems. Twenty-one patients with full thickness rectal biopsy-proven HD underwent one-stage TAP. Average follow-up was 28 months. One early postoperative EC and three more late attacks of EC were observed. All survived patients had normal bowel habits. Three patients had perianal excoriations, three patients soiling, seven cases required anal dilatations and four patients experienced a diarrhea after surgery. We have been informed that four patients died after discharge from hospital. Two of them were a sudden death (one patient had metabolic problems, the other might have had an EC attack). The cause of death of one patient with an associated Down syndrome was a severe pneumonia, and one other case died of a septic shock of unknown etiology. None of these patients had a diarrhea or abdominal distention, which could have been an evidence of an EC attack prior to their deaths. We observed similar fatal cases, when reviewed the published series in the literature. There might be a hidden mortality within the long-term period after TAP for HD. Therefore, we recommend a close follow-up for all patients with any associated health problem and those from low socioeconomic regions after one-stage pull-through.
一期经肛门拖出术(TAP)已成为治疗先天性巨结肠(HD)的标准确定性手术。该手术的短期效果似乎极佳,但长期预后仍不明确。我们评估了接受一期TAP治疗患者的发病率和死亡率,并对相关文献进行了回顾。我们对21例HD患者实施了无结肠造口的TAP手术。主要观察指标包括年龄、性别、手术中的并发症、术后小肠结肠炎(EC)发作、术后排便问题及死亡率。所有患者均通过电话随访,获取其临床和功能结局。我们还根据术后问题对文献中TAP的病例系列进行了回顾。21例经全层直肠活检证实为HD的患者接受了一期TAP手术。平均随访时间为28个月。观察到1例术后早期EC发作和另外3例晚期EC发作。所有存活患者的排便习惯均正常。3例患者有肛周皮肤擦伤,3例患者有大便失禁,7例患者需要进行肛门扩张,4例患者术后出现腹泻。我们得知有4例患者出院后死亡。其中2例为猝死(1例患者有代谢问题,另1例可能发生了EC发作)。1例合并唐氏综合征患者的死亡原因是严重肺炎,另1例死于病因不明的感染性休克。这些患者在死亡前均无腹泻或腹胀,而腹泻或腹胀可能是EC发作的迹象。在回顾文献中已发表的系列研究时,我们也观察到了类似的致命病例。对于HD患者接受一期拖出术后的长期随访中,可能存在隐匿性死亡情况。因此,我们建议对所有有任何相关健康问题的患者以及来自社会经济地位较低地区的患者在一期拖出术后进行密切随访。